Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.

Autor:	Wilcox JA; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Chukwueke UN; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Aizer AA; Department of Radiation Oncology, Brigham and Women's Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Bale TA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Brandsma D; Department of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Brastianos PK; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Chang S; Division of Neuro-Oncology, Department of Neurosurgery, University of San Francisco California, San Francisco, California, USA., Daras M; Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA., Forsyth P; Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Garzia L; Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada., Glantz M; Department of Neurosurgery, Penn State College of Medicine, Hershey, Pennsylvania, USA., Oliva ICG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kumthekar P; The Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Le Rhun E; Departments of Neurology and Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland., Nagpal S; Division of Neuro-Oncology, Department of Neurology, Stanford University School of Medicine, Stanford, California, USA., O'Brien B; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pentsova E; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Lee EQ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Remsik J; Laboratory for Immunology of Metastatic Ecosystems, Center for Cancer Biology, VIB, Leuven, Belgium.; Department of Oncology, KU Leuven, Leuven, Belgium., Rudà R; Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science Hospital, Turin, Italy.; Department of Neurology, Castelfranco Veneto and Treviso Hospitals, Castelfranco Veneto, Italy., Smalley I; Department of Tumor Biology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Taylor MD; Division of Neurosurgery, Department of Surgery, Texas Children's Hospital, Houston, Texas, USA.; Neuro-oncology Research Program, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas., Weller M; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland., Wefel J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yang JT; Department of Radiation Oncology, Department of Radiation Oncology, New York University School of Medicine, New York, New York, USA., Young RJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Boire AA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Neurology, Brain Tumor Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jazyk:	angličtina
Zdroj:	Neuro-oncology [Neuro Oncol] 2024 Oct 03; Vol. 26 (10), pp. 1781-1804.
DOI:	10.1093/neuonc/noae103
Abstrakt:	Leptomeningeal metastases (LM) are increasingly becoming recognized as a treatable, yet generally incurable, complication of advanced cancer. As modern cancer therapeutics have prolonged the lives of patients with metastatic cancer, specifically in patients with parenchymal brain metastases, treatment options, and clinical research protocols for patients with LM from solid tumors have similarly evolved to improve survival within specific populations. Recent expansions in clinical investigation, early diagnosis, and drug development have given rise to new unanswered questions. These include leptomeningeal metastasis biology and preferred animal modeling, epidemiology in the modern cancer population, ensuring validation and accessibility of newer leptomeningeal metastasis diagnostics, best clinical practices with multimodality treatment options, clinical trial design and standardization of response assessments, and avenues worthy of further research. An international group of multi-disciplinary experts in the research and management of LM, supported by the Society for Neuro-Oncology and American Society of Clinical Oncology, were assembled to reach a consensus opinion on these pressing topics and provide a roadmap for future directions. Our hope is that these recommendations will accelerate collaboration and progress in the field of LM and serve as a platform for further discussion and patient advocacy. (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu